Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease

Author： Chan Phylinda   Nutt John   Holford Nicholas  

Publisher： Springer Publishing Company

ISSN： 1567-567X

Source： Journal of Pharmacokinetics and Pharmacodynamics, Vol.32, Iss.3-4, 2005-08, pp. : 459-484

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations

By Stocchi Fabrizio  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1399-1407

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic-Pharmacodynamic Relationship of Levodopa with and without Tolcapone in Patients with Parkinson's Disease

By Baas H.  

Clinical Pharmacokinetics, Vol. 40, Iss. 5, 2001-01 ,pp. : 383-393

Adis International

Access to resources Recommend Favorite

Alternatives to Levodopa in the Initial Treatment of Early Parkinson’s Disease

By Lees Andrew  

Drugs & Aging, Vol. 22, Iss. 9, 2005-01 ,pp. : 731-740

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson's Disease

By Deleu D.  

Clinical Pharmacokinetics, Vol. 41, Iss. 4, 2002-01 ,pp. : 261-309

Adis International

Access to resources Recommend Favorite

Ropinirole in the treatment of Parkinson’s disease

By Zesiewicz T.A.   Hauser R.A.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 697-710

Informa Healthcare

Access to resources Recommend Favorite